University of Chicago Cancer Center
Michelle Le Beau, Ph.D.
Director
5841 South Maryland Avenue, MC 2115
Chicago, Illinois 60637-1470
Tel: (773) 702-6180
Fax: (773) 702-9311
Information on University of Chicago Cancer Center
The University of Chicago Comprehensive Cancer Center (UCCCC) was founded in 1973, and has been supported by continuous NCI–funding. The UCCCC is one of two NCI–designated Comprehensive Cancer Centers in Illinois, and has a long tradition of excellence in clinical and basic science cancer research, training, and cancer care and a more recently, expanded expertise in population research. The mission of the Center is the discovery of new information to improve the understanding of the determinants of cancer, to develop cures for cancer, and to prevent cancer. By promoting collaboration among a diverse and dedicated team of outstanding basic, translational, and population researchers, together with clinical researchers and caregivers, the Center aims to move laboratory findings to the next generation of therapies and potential cures. The UCCCC is a major referral center for patients with cancer throughout the Chicago metropolitan area, the Midwest, and the nation, seeing close to 6000 new cancer patients annually. At the same time, being situated on the Southside of Chicago, the institution has a strong reputation for providing care to underserved populations, while integrating a major emphasis on health disparities research.
The UCCCC has approximately 215 members who receive close to $100 million in peer–reviewed funding annually. Members belong to one of six scientific programs: Cell Signaling and Gene Regulation, Hematopoiesis and Hematological Malignancies, Immunology and Cancer, Clinical and Experimental Therapeutics, Advanced Imaging, and Cancer Risk and Prevention. The Center is a leader in experimental therapeutics, early–phase clinical trials, and the development of novel treatment strategies (e.g., organ preservation); the institution holds NCI Phase I and II grants/contracts, and serves as the host institution for the Cancer and Leukemia Group B (CALGB). In addition, faculty in the Center have gained international recognition for their characterization of hematological malignant diseases, pharmacogenomics/pharmacogenetics of anti–cancer agents research (UCCCC is the lead for the NIH Pharmacogenetics of Anticancer Agents Research Group (PAAR)), and identification of patients, particularly minority populations, at high risk for cancer. These efforts translate into approximately 1000 patients being enrolled on over 200 protocols annually. UCCCC’s strength in health disparities is evidenced by two large NIH awards — a Center for Interdisciplinary Health Disparities Research grant (one of eight nationwide), which is exploring the causes of breast cancer in African–American women, and a Specialized Program in Research Excellence in Breast Cancer (one of 11 nationwide), which focuses on recent advances in genetics to benefit women who are at risk of developing an aggressive form of breast cancer, which disproportionately affects African American women at a young age.
The UCCCC works closely with Argonne National Laboratory (ANL), with a number of academic units spanning the two institutions. One such joint initiative, The Institute for Genomics and Systems Biology, focuses on genomics and systems biology approaches to understand genome function and evolution, uncover new diagnostic and therapeutic targets, and discover new strategies for complex human diseases with a major focus on cancer. Finally, in the summer of 2009, NorthShore University HealthSystem, a comprehensive healthcare delivery system including four hospitals that serve the greater North Shore and northern Illinois communities, became a formal University of Chicago affiliate, thus extending the reach of the University of Chicago’s clinical, research and teaching missions.
*Source: National Cancer Institute

Leave a Comment